BioSpace - Print News Article

Novartis Corporation (NVS) Edges Ahead of Merck KGaA (MKGAF.PK) in MS Race; Novartis's Lower Dose of FTY720 Filed for U.S. and EU Approval; Merck's Cladribine Faces FDA Delay 1/21/2010 7:18:11 AM Reuters -- Swiss drugmaker Novartis has edged ahead of German rival Merck KGaA in the race to get the first oral multiple sclerosis treatment to market, having now filed for approval in the United States and Europe.

Novartis Corporation (NVS) Edges Ahead of Merck KGaA (MKGAF.PK) in MS Race; Novartis's Lower Dose of FTY720 Filed for U.S. and EU Approval; Merck's Cladribine Faces FDA Delay
1/21/2010 7:18:11 AM

Reuters -- Swiss drugmaker Novartis has edged ahead of German rival Merck KGaA in the race to get the first oral multiple sclerosis treatment to market, having now filed for approval in the United States and Europe.